Le vieux caporal : drame en cinq actes. [suivi de] Diane de lys et de camélias, ou La femme du monde légère, liée à un homme bilieux qui n'entend pas la plaisanterie : grande parodie en 3 petits tableaux. Livr. 121 / par MM. Dumanoir et d'Ennery ; par MM. Delacour et Lambert Thiboust

Collection : Théâtre contemporain illustré ; 121e et 122e livraisons

Livre des Morts de Nésyménou. Egyptien 121

Fragment 3 :Col. 1 + vignette : chapitre 28 (formule pour empêcher qu'on ne retire son coeur au défunt). La vignette montre le coeur du défunt et une divinité assise sur une maison.Col. 2 + vignette : chapitre 30B (formule pour empêcher que s'oppose le coeur du défunt). La vignette représente un scarabée.Col. 3 + vignette : chapitre 31 (formule pour repousser un crocodile venu pour enlever la magie-hékaou du défunt).Fragment 1 : la vignette montre le défunt armé d'une pique, qui devait probablement transpercer un animal néfaste.Fragment 2 :Col. 1 + vignette : chapitre 32 (formule pour repousser un crocodile venu pour enlever la magie-hékaou d'un Bienheureux de son contrôle dans la nécropole). La vignette montre deux crocodiles qui devaient être transpercés par le défunt.Col. 2 + vignette : chapitre 33 (formule pour repousser un serpent). La vignette montre le défunt transperçant un insecte (on attendrait un serpent).Col. 3 + vignette : chapitre 37 (formule pour repousser les deux amies). La vignette montre le défunt transperçant un serpent enroulé.Col. 4 + vignette (très fragmentaires) : ?

Resolución No. 121: Por la cual se decide una revocatoria directa

Servicios registrales

Synthesis and in vitro evaluation of potential antichagasic hydroxymethyinitrofurazone (NFOH-121): A new nitrofurazone prodrug

The synthesis of mutual prodrugs of nitrofurazone with primaquine, using specific and nonspecific spacer groups, has been previously attempted seeking selective antichagasic agents. The intermediate reaction product, hydroxymethylnitrofurazone (NFOH-121), was isolated and tested in LLC-MK2 culture cells infected with trypomastigotes forms of Trypanosoma cruzi showing higher trypanocidal activity than nitrofurazone and benznidazol in all stages. The mutagenicity tests showed that the prodrug was less toxic than the parent drug. Degradation assays were carried out in pH 1.2 and 7.4. (C) 2003 Elsevier Ltd. All rights reserved.

Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry

OBJECTIVES. The purpose of this study was to obtain data on the association of antiphospholipid antibodies with clinical manifestations in childhood and to enable future studies to determine the impact of treatment and long-term outcome of pediatric antiphospholipid syndrome.PATIENTS and METHODS. A European registry extended internationally of pediatric patients with antiphospholipid syndrome was established as a collaborative project of the European Antiphospholipid Antibodies Forum and Lupus Working Group of the Pediatric Rheumatology European Society. To be eligible for enrollment the patient must meet the preliminary criteria for the classification of pediatric antiphospholipid syndrome and the onset of antiphospholipid syndrome must have occurred before the patient's 18th birthday.RESULTS. As of December 1, 2007, there were 121 confirmed antiphospholipid syndrome cases registered from 14 countries. Fifty-six patients were male, and 65 were female, with a mean age at the onset of antiphospholipid syndrome of 10.7 years. Sixty (49.5%) patients had underlying autoimmune disease. Venous thrombosis occurred in 72 (60%), arterial thrombosis in 39 (32%), small-vessel thrombosis in 7 (6%), and mixed arterial and venous thrombosis in 3 (2%). Associated nonthrombotic clinical manifestations included hematologic manifestations (38%), skin disorders (18%), and nonthrombotic neurologic manifestations (16%). Laboratory investigations revealed positive anticardiolipin antibodies in 81% of the patients, anti-beta(2)-glycoprotein I antibodies in 67%, and lupus anticoagulant in 72%. Comparisons between different subgroups revealed that patients with primary antiphospholipid syndrome were younger and had a higher frequency of arterial thrombotic events, whereas patients with antiphospholipid syndrome associated with underlying autoimmune disease were older and had a higher frequency of venous thrombotic events associated with hematologic and skin manifestations.CONCLUSIONS. Clinical and laboratory characterization of patients with pediatric antiphospholipid syndrome implies some important differences between antiphospholipid syndrome in pediatric and adult populations. Comparisons between children with primary antiphospholipid syndrome and antiphospholipid syndrome associated with autoimmune disease have revealed certain differences that suggest 2 distinct subgroups. Pediatrics 2008; 122: e1100-e1107